Fremanezumab May Offer Prevention for Refractory Migraine Fremanezumab May Offer Prevention for Refractory Migraine

A CGRP agent in development to prevent chronic migraine demonstrates efficacy in patients previously treated with topiramate or onabotulinumtoxinA.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news